Adverum Biotech
Yixin Li has extensive experience in the biotechnology field. From 2020 to the present, they have been working as a Principal Scientist at Adverum Biotechnologies, Inc., where they have focused on developing a novel method to measure AAV particle full/empty ratio and correct encapsulated DNA. Prior to this, they worked as a Sr. Scientist and Scientist III at the same company, where they developed and improved assays to quantify AAV genome titer, residual DNA, and TCID50. Yixin Li also has previous experience at Thermo Fisher Scientific, Life Technologies, APPLIED BIOSYSTEMS, and Kaiser Permanente, holding various scientific roles in research and development, technology transfer, and diagnostic laboratory settings.
Yixin Li has a Bachelor of Science degree in Public Health from Beijing Medical University (now Peking University Medical School). Yixin also holds a Master of Science degree in Toxicology from the same institution. Later, they pursued a Doctor of Philosophy (Ph.D.) in Toxicology/Molecular Biology at the University of Kentucky. After completing their Ph.D., they became a Postdoctoral Fellow at Baylor College of Medicine.
Adverum Biotech
9 followers
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.